Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 17/20 | 0.62 |
| ▸ | PIK3CD | O00329 | 15/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 14/20 | 0.62 |
| ▸ | MTOR | P42345 | 8/20 | 0.60 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22411334 | 0.87 | HRH4 (0.52) | PIK3CAPIK3CDPIK3CGMTOR | |
| SCHEMBL11855240 | 0.85 | HRH4 (0.51) | PIK3CAPIK3CDPIK3CGMTOR | |
| SCHEMBL25724448 | 0.83 | PIK3CA (0.62) | PIK3CAPIK3CDPIK3CGMTORPIK3R1 | |
| SCHEMBL27272553 | 0.83 | PIK3CA (0.62) | PIK3CAPIK3CDPIK3CGMTORPIK3R1 | |
| SCHEMBL11848455 | 0.83 | PIK3CA (0.58) | PIK3CAPIK3CDPIK3CGMTORPIK3R1 | |
| SCHEMBL11857620 | 0.81 | PIK3CA (0.46) | PIK3CAPIK3CDPIK3CGMTOR | |
| SCHEMBL25277910 | 0.80 | PIK3CD (0.61) | PIK3CAPIK3CDPIK3CGMTORPIK3R1 | |
| SCHEMBL30456000 | 0.80 | PIK3CA (0.58) | PIK3CAPIK3CDPIK3CGMTORPIK3R1 | |
| SCHEMBL16166910 | 0.79 | SMN1; SMN2 (0.49) | PIK3CAPIK3CDPIK3CGMTORPOLB | |
| SCHEMBL1711491 | 0.79 | PTK2 (0.65) | PIK3CAPIK3CDPIK3CGMTORPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288589-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. | 2025-09-18 | — | — | US | disclosed |
| EP-4444289-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| WO-2023107592-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107592-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| EP-4161926-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Yumanity Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-8563540-B2 | Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130225557-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-8440651-B2 | Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-14 | — | — | US | disclosed |
| EP-2539337-A1 | PYRIDO[3,2-D]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| US-20110257170-A1 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO SA (CH) | 2011-10-20 | — | — | US | disclosed |
| US-20110257170-A1 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO SA (CH) | 2011-10-20 | — | — | US | disclosed |
| US-20110257170-A1 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO SA (CH) | 2011-10-20 | — | — | US | disclosed |
| WO-2011101429-A1 | PYRIDO[3,2-D]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | WO | disclosed |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | US | disclosed |
| WO-2010037765-A2 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO S.A. (CH) | 2010-04-08 | — | — | WO | disclosed |
| US-3939268-A | 2,4-Diamino substituted pyridol(3,2-d)pyrimidine as antithrombotic agents | BOEHRINGER INGELHEIM GMBH (DT) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225557-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3CD 2/4885PIK3CG 4/4885 |
| US-20110257170-A1 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | PIK3CA, PIK3CD, PIK3CG | PIK3CA 1/4885PIK3CD 2/4885PIK3CG 3/4885 |
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | PNPO, DPYD, PYGB | PIK3CA 3369/4885PIK3CD 3769/4885PIK3CG 3429/4885 |
| US-20250288589-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | PNPO, DPYD, PYGB | PIK3CA 3369/4885PIK3CD 3769/4885PIK3CG 3429/4885 |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3CD 2/4885PIK3CG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.